Giuliana Grossi

Baricitinib shows promising results for severe alopecia areata, with more than half of patients experiencing significant hair regrowth within a year.

Obstructive sleep apnea may increase Parkinson disease risk, but early CPAP treatment could significantly reduce this risk.

Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.

Explore how patient experience data shapes regulatory drug decisions, enhancing the patient-focused drug development initiative for better treatment outcomes.

A look back at the breakthroughs in pulmonary fibrosis research, including FDA-approved treatments and innovative diagnostic techniques.

Advances in radiopharmaceuticals, precision medicine, and the importance of diversity in clinical trials for multiple myeloma and cancer care were among the most popular articles with readers in 2025.

Studies indicate that ultrasound-based AI models significantly outperform sonographers in diagnosing ovarian cancer.

Discover the latest breakthroughs in myasthenia gravis treatment, including rozanolixizumab and nipocalimab, and insights on disease burden and dysphagia indicators.

Federal policy changes, the push for fair pricing, and growing competition in the drug pipeline were major topics at this year’s meeting.

Trump secures new pricing deals with 9 drugmakers, advancing his effort to align US drug costs with Europe and expand direct-to-consumer purchasing.

New research reveals that quick sleep onset may lower hypertension risk, challenging traditional views on sleepiness and cardiovascular health.

Reflect on the challenges in health equity, care access, and policy shifts impacting health insurance and clinical research in 2025.

Marco del Riccio, MD, explains that the Flunomics report helped to identify gaps in US vaccine coverage and influenza surveillance during the 2024-2025 season.

The editors in chief of AJMC discuss the key managed care research and news from 2025 as the journal celebrated its 30th anniversary.

The past year has seen multiple changes in the HIV space that have long-term effects when it comes to ending the epidemic.

This year’s most-read articles on CKD highlighted research and insights on drug approvals, guidelines, and value-based care.

Today, the FDA issued new guidance allowing de-identified real-world evidence in certain medical device applications, removing a barrier to using large data sources.

The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.

Blinatumomab enhances survival in pediatric B-cell ALL, yet homecare challenges hinder its outpatient delivery.

Pirtobrutinib significantly improved progression-free survival in treatment-naïve CLL compared with bendamustine plus rituximab.

Five key oncology FDA approvals came through last month, expanding treatment options across multiple cancer types.

Psychotherapy is key in reducing risk of depression relapse when tapering antidepressant medication.

Cervical cancer screening adherence drops below 10%, highlighting confusion over evolving guidelines and significant disparities in HPV awareness.

Research highlights the complex cognitive difficulties faced by breast cancer survivors, emphasizing the need for multifaceted treatment approaches, says Xiaotong Li, PhD, MS.

Discover key insights from the ERS Congress 2025, highlighting advancements in pulmonary fibrosis treatment and the promising role of nerandomilast.

In case you missed it: the top 5 highlights from the Menopause Society's 2025 Annual Meeting.

At SABCS 2025, Amrita Basu, PhD, underscores that effective AI use for breast cancer care depends on human oversight.

Discover more about seasonal affective disorder in this interview with Craig Sawchuk, PhD, LP, clinical psychologist at Mayo Clinic.

Innovative deep proteomic profiling reveals promising results from a blood-based test for early breast cancer, showcasing high sensitivity and specificity, explains Justin Drake, PhD.

A groundbreaking in vivo CAR T-cell therapy shows promise for treating multiple myeloma, potentially revolutionizing cancer care with quicker, safer treatments.